XTX101
Advanced solid tumors
Phase 1Active, Recruiting
Key Facts
About Xilio Therapeutics
Xilio Therapeutics is developing a new class of tumor-activated immuno-oncology therapies designed to overcome the dose-limiting toxicities of systemic agents. Its core achievement is a clinically-validated masking technology platform that has generated two Phase 1 candidates and attracted strategic partnerships with major pharmaceutical companies. The company's strategy is to leverage this platform to unlock the full therapeutic potential of proven mechanisms like CTLA-4 inhibition and IL-2, confining their potent activity to the site of the tumor to improve the therapeutic index.
View full company profileTherapeutic Areas
Other Advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |